| Name | Title | Contact Details |
|---|---|---|
Claudia Kuri |
Chief Operating Officer | Profile |
Glenn Galloway |
Executive VP Technology & Integrations | Profile |
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
PeproTech is a Rocky Hill, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AristaMD develops solutions to improve patient outcomes through efficiency in healthcare.
White Oak Manor-Shelby is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Loyale is reinventing the way healthcare providers engage with their patients financially. With Loyale`s end-to-end suite of solutions, providers of all types and configurations are elevating their patients` financial experiences to a level that compares with their clinical experiences. With Loyale, providers build durable, trusting relationships with patients. They also increase revenues, reduce staff time & stress, and minimize bad debt.